216 related articles for article (PubMed ID: 31082785)
1. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
Rendle DI; Doran G; Ireland J; Edwards S
Domest Anim Endocrinol; 2019 Jul; 68():135-141. PubMed ID: 31082785
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction.
McFarlane D; Banse H; Knych HK; Maxwell LK
J Vet Pharmacol Ther; 2017 Apr; 40(2):158-164. PubMed ID: 27301465
[TBL] [Abstract][Full Text] [Related]
3. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
[TBL] [Abstract][Full Text] [Related]
4. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review.
Tatum RC; McGowan CM; Ireland JL
Vet J; 2020 Dec; 266():105562. PubMed ID: 33323174
[TBL] [Abstract][Full Text] [Related]
6. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC
BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825
[TBL] [Abstract][Full Text] [Related]
7. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
Beech J; Boston R; Lindborg S; Russell GE
J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045
[TBL] [Abstract][Full Text] [Related]
8. Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses.
Rendle DI; Duz M; Beech J; Parkin T; Durham AE
J Vet Intern Med; 2015 Jan; 29(1):355-61. PubMed ID: 25312676
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cortisol and ACTH responses after administration of thyrotropin releasing hormone in normal horses and those with pituitary pars intermedia dysfunction.
Beech J; Boston R; Lindborg S
J Vet Intern Med; 2011; 25(6):1431-8. PubMed ID: 22092639
[TBL] [Abstract][Full Text] [Related]
10. Fecal strongyle egg counts in horses with suspected pre-clinical pituitary pars intermedia dysfunction before and after treatment with pergolide.
Christen G; Gerber V; van der Kolk JH; Frey CF; Fouché N
Vet J; 2018 May; 235():60-62. PubMed ID: 29704940
[TBL] [Abstract][Full Text] [Related]
11. The effect of pergolide mesylate on adrenocorticotrophic hormone responses to exogenous thyrotropin releasing hormone in horses.
Durham AE
Vet J; 2022 Jul; 285():105831. PubMed ID: 35477010
[TBL] [Abstract][Full Text] [Related]
12. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction.
Rendle DI; Litchfield E; Heller J; Hughes KJ
Equine Vet J; 2014 Jan; 46(1):113-7. PubMed ID: 23742059
[TBL] [Abstract][Full Text] [Related]
13. Preliminary study on the effects of pergolide on left ventricular function in the horses with pituitary pars intermedia dysfunction.
Gehlen H; Fisch J; Merle R; Trachsel DS
J Vet Sci; 2021 Sep; 22(5):e64. PubMed ID: 34553515
[TBL] [Abstract][Full Text] [Related]
14. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants.
McFarlane D; Beech J; Cribb A
Domest Anim Endocrinol; 2006 May; 30(4):276-88. PubMed ID: 16115743
[TBL] [Abstract][Full Text] [Related]
15. α-Melanocyte--stimulating hormone and adrenocorticotropin concentrations in response to thyrotropin-releasing hormone and comparison with adrenocorticotropin concentration after domperidone administration in healthy horses and horses with pituitary pars intermedia dysfunction.
Beech J; McFarlane D; Lindborg S; Sojka JE; Boston RC
J Am Vet Med Assoc; 2011 May; 238(10):1305-15. PubMed ID: 21568777
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of pergolide after intravenous administration to horses.
Rendle DI; Hughes KJ; Doran GS; Edwards SH
Am J Vet Res; 2015 Feb; 76(2):155-60. PubMed ID: 25629913
[TBL] [Abstract][Full Text] [Related]
17. Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group.
Secombe CJ; Bailey SR; de Laat MA; Hughes KJ; Stewart AJ; Sonis JM; Tan R
Aust Vet J; 2018 Jul; 96(7):233-242. PubMed ID: 29862508
[TBL] [Abstract][Full Text] [Related]
18. The effect of freeze-thaw cycles on determination of immunoreactive plasma adrenocorticotrophic hormone concentrations in horses.
Hu K; Stewart AJ; Yuen KY; Hinrichsen S; Dryburgh EL; Bertin FR
J Vet Intern Med; 2020 May; 34(3):1350-1356. PubMed ID: 32255541
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of seasonal influences on adrenocorticotropic hormone response to the thyrotropin-releasing hormone stimulation test and its accuracy for diagnosis of pituitary pars intermedia dysfunction.
Adams AA; Siard-Altman MH; Reedy SE; Barker D; Elzinga S; Sanz MG; Urschel K; Ireland JL
Vet J; 2023; 300-302():106035. PubMed ID: 37802466
[TBL] [Abstract][Full Text] [Related]
20. Pergolide dosing compliance and factors affecting the laboratory control of equine pituitary pars intermedia dysfunction.
Hague N; Durham AE; Menzies-Gow NJ
Vet Rec; 2021 Jul; 189(1):e142. PubMed ID: 33759215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]